Is Clovis's rociletinib better than other lung cancer treatments, FDA committee to be asked

An advisory committee of the US Food and Drug Administration will question on Tuesday whether rociletinib, the lung cancer drug of USA-based Clovis Oncology (Nasdaq: CLVS), is any more effective than drugs which are already available.

However, ahead of the meeting, negative briefing papers from FDA staffers saw Clovis shares plunge as much as19% on Monday.

Rociletinib is indicated for the treatment of patients with epidermal growth factor receptor (EGFR) mutation positive metastatic non-small cell lung cancer, who have been previously treated with EGFR-targeted therapy and who have the EGFR T790M mutation, as detected by an FDA-approved test.